PACAP has demonstrated beneficial effects for MS in several studies, including an improvement of lesion severity and amelioration of disability in mouse models, and a downregulation of IL-6 in human studies, suggesting a robust anti-inflammatory mechanism of action [63,64]. This evidence concerns the gene IL6 and myeloid sarcoma.